Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
Completed
Heidelberg University
N/A
2005-05-01
Inhaled nitrous oxide (iNO) will be compared to aerosolized iloprost (ILO) in pediatric
patients after cardiac surgery with pulmonary hypertension. The hypothesis is that iloprost
is more effective in preventing pulmonary hypertensive crises.
Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
Completed
Bayer
2005-04-01
This is an observational study to monitor the continued effectiveness of Ventavis (inhaled
iloprost) in the long-term. The study observes the effects and the safety of Ventavis
inhalation therapy over at least 2 years and up to 4 years. A total of 54 patients from
around 30 study sites in Europe will be included in the study. This observational study will
collect information in patients receiving a medication that is already available on
prescription in the participating countries. Ventavis is used to treat moderate cases of
primary pulmonary hypertension.
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
Terminated
Actelion
Phase 3
2006-02-01
The purpose of this multi-center international trial is to evaluate the safety and
effectiveness of adding iloprost or placebo (an inactive substance that contains no active
study drug) to sildenafil therapy for pulmonary arterial hypertension (PAH). The study will
also examine whether patients on sildenafil can reduce the number of iloprost inhalations
from the approved 6 doses per day to 4 doses per day.
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
Completed
University of Cincinnati
Phase 4
2006-11-01
This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension
with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
